Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

General Information

Summary The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Clinical trials phase Phases 1/2
Start date (estimated) 2015-03-01
End date (estimated) 2018-12-31
Clinical feature
Label Spinal Cord Injury
Description Traumatic damage of the spinal cord.

Administrative Information

NCT number NCT02302157
ICTRP weblink
Other study identifiers
Name AST-OPC1-01
Regulatory body approval
Public contact
Public email
Sponsors Asterias Biotherapeutics, Inc

Cell Line

Stem cell lines obtained from


Recruitment Status Completed
Estimated number of participants 25